New histology-based use for Alimta
US pharmaceutical group Eli Lilly's cancer drug Alimta (permetrexed for injection) has been recommended for marketing by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in combination with cisplatin for the first-line treatment of patients with locally-advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
The Indianapolis-headquartered firm said that this novel use of histology opens the door for a more tailored approach to treating the world's most common cause of cancer deaths.
The CHMP recommendation was based on Phase III data from 1,752 patients which found that the approved Alimta regimen was non-inferior to the same background regimen plus Gemzar (gemcitabine for injection) in the first-line NSCLC setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze